James Gordon
Stock Analyst at Barclays
(2.58)
# 2,238
Out of 5,182 analysts
11
Total ratings
66.67%
Success rate
16.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Gordon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GSK GSK plc | Downgrades: Underweight | n/a | $50.53 | - | 1 | Jan 6, 2026 | |
| ARGX argenx SE | Maintains: Overweight | $925 → $1,100 | $807.55 | +36.21% | 8 | Dec 8, 2025 | |
| GRFS Grifols | Maintains: Neutral | $7.6 → $10 | $8.40 | +22.62% | 1 | Jun 17, 2025 | |
| GMAB Genmab | Downgrades: Neutral | n/a | $27.89 | - | 1 | Aug 20, 2024 |
GSK plc
Jan 6, 2026
Downgrades: Underweight
Price Target: n/a
Current: $50.53
Upside: -
argenx SE
Dec 8, 2025
Maintains: Overweight
Price Target: $925 → $1,100
Current: $807.55
Upside: +36.21%
Grifols
Jun 17, 2025
Maintains: Neutral
Price Target: $7.6 → $10
Current: $8.40
Upside: +22.62%
Genmab
Aug 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $27.89
Upside: -